Drugmaker AbbVie is raising its takeover offer for Irish pharmaceutical company Shire for a fourth time as it attempts to secure a tax inversion deal. Under the new offer, AbbVie raised its cash-and-stock bid by 11% to $51.6 billion. Shire already rejected AbbVie's previous bid of $46 billion, saying it significantly undervalued the company. As part of the deal, AbbVie would acquire Shire and move the combined company's tax home to the U.K., which has a main corporate tax rate of 21%, below the U.S. federal corporate tax rate of 35%. Shire did not immediately reject the offer, saying its board would meet to consider the proposal.

If you liked this article you might like

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

AbbVie Appears Ready to Start a New Advance at Any Time

AbbVie Appears Ready to Start a New Advance at Any Time

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here